| Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma CC Pinnix, JR Gunther, BS Dabaja, P Strati, P Fang, MC Hawkins, ... Blood Advances 4 (13), 2871-2883, 2020 | 174 | 2020 |
| Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma P Strati, S Ahmed, P Kebriaei, LJ Nastoupil, CM Claussen, G Watson, ... Blood Advances 4 (13), 3123-3127, 2020 | 144 | 2020 |
| Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma P Strati, S Ahmed, F Furqan, LE Fayad, HJ Lee, SP Iyer, R Nair, ... Blood, The Journal of the American Society of Hematology 137 (23), 3272-3276, 2021 | 124 | 2021 |
| Immunotherapy-associated hemolytic anemia with pure red-cell aplasia R Nair, S Gheith, SG Nair New England Journal of Medicine 374 (11), 1096-1097, 2016 | 81 | 2016 |
| CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity U Greenbaum, P Strati, RM Saliba, J Torres, G Rondon, Y Nieto, C Hosing, ... Blood advances 5 (14), 2799-2806, 2021 | 75 | 2021 |
| Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma P Strati, LJ Nastoupil, J Westin, LE Fayad, S Ahmed, NH Fowler, ... Blood advances 4 (16), 3943-3951, 2020 | 75 | 2020 |
| A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy CK Stein-Thoeringer, NY Saini, E Zamir, V Blumenberg, ML Schubert, ... Nature medicine 29 (4), 906-916, 2023 | 64 | 2023 |
| Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)‐outcomes and mutation profile from venetoclax resistant MCL patients S Zhao, R Kanagal‐Shamanna, L Navsaria, CY Ok, S Zhang, K Nomie, ... American journal of hematology 95 (6), 623-629, 2020 | 64 | 2020 |
| Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study LJ Teoh, AL Solebo, JS Rahi, J Abbott, W Abdullah, G Adams, L Allen, ... The Lancet Child & Adolescent Health 5 (3), 190-200, 2021 | 51 | 2021 |
| Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL P Jain, S Zhang, R Kanagal-Shamanna, CY Ok, K Nomie, GN Gonzalez, ... Blood Advances 4 (6), 1038-1050, 2020 | 51 | 2020 |
| Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma S Zhang, VC Jiang, G Han, D Hao, J Lian, Y Liu, R Zhang, J McIntosh, ... Nature communications 12 (1), 2877, 2021 | 44 | 2021 |
| The promise of CAR T-cell therapy in aggressive B-cell lymphoma R Nair, SS Neelapu Best practice & research Clinical haematology 31 (3), 293-298, 2018 | 44 | 2018 |
| Car T-cells R Nair, J Westin Immunotherapy, 215-233, 2020 | 42 | 2020 |
| Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma NY Saini, DM Swoboda, U Greenbaum, J Ma, RD Patel, K Devashish, ... Blood cancer discovery 3 (5), 385-393, 2022 | 36 | 2022 |
| Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial ML Wang, P Jain, S Zhao, HJ Lee, L Nastoupil, L Fayad, CY Ok, ... The Lancet Oncology 23 (3), 406-415, 2022 | 35 | 2022 |
| Safety of CAR T-cell therapy in kidney transplant recipients O Mamlouk, R Nair, SP Iyer, A Edwards, SS Neelapu, RE Steiner, ... Blood, The Journal of the American Society of Hematology 137 (18), 2558-2562, 2021 | 34 | 2021 |
| Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma J Westin, RE Davis, L Feng, F Hagemeister, R Steiner, HJ Lee, L Fayad, ... Journal of Clinical Oncology 41 (4), 745, 2023 | 31 | 2023 |
| Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma HJJ Cherng, R Sun, B Sugg, R Irwin, H Yang, CC Le, Q Deng, L Fayad, ... Blood, The Journal of the American Society of Hematology 140 (5), 504-515, 2022 | 30 | 2022 |
| Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy A Al Zaki, L Feng, G Watson, SA Ahmed, H Mistry, LJ Nastoupil, ... Blood Advances 6 (9), 2867-2871, 2022 | 29 | 2022 |
| Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL) LJ Nastoupil, JR Westin, FB Hagemeister, HJ Lee, L Fayad, F Samaniego, ... Blood 134, 125, 2019 | 27 | 2019 |
